share_log

B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target

B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target

A股銀行將Beam Therapeutics的評級下調至中性,宣佈35美元的目標股價
Benzinga ·  2023/12/15 08:37

B of A Securities analyst Greg Harrison downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and announces $35 price target.

Bof A證券分析師格雷格·哈里森將Beam Therapeutics(納斯達克股票代碼:BEAM)的評級從買入下調至中性,並宣佈了35美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論